% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • themicrokid themicrokid Nov 29, 2012 10:11 AM Flag

    The right SRPT deal might make VRTX management look like geniuses!

    My model is $440 million revenue on 1463 US patients. Next 4 exons will bring many patients, US, Europe, Japan. Think 11,000 at 60% penetration. If GSK/Prosensa continue to have toxicity issues they will come under pressure and allow Eteplirsen in EU and Japan for a royalty.

    Many more possibilities in the exon skipping world to come.

    Sentiment: Buy

126.41-2.42(-1.88%)12:13 PMEDT